Murine neuroblastoma vaccines produced by retroviral transfer of MHC class II genes.

abstract：:Combination therapy with replicative oncolytic viruses is a recent topic in innovative cancer therapy, but few studies have examined the efficacy of oncolytic adenovirus plus replication-deficient adenovirus carrying a suicide gene. We aim to evaluate whether an E1A, E1B double-restricted oncolytic adenovirus, AxdAdB-...

journal_title：Cancer gene therapy

authors： Fukuda K,Abei M,Ugai H,Kawashima R,Seo E,Wakayama M,Murata T,Endo S,Hamada H,Hyodo I,Yokoyama KK

更新日期：2009-02-01 00:00:00

abstract：:Typically, gene transfer strategies utilize a promoter/transgene arrangement that treat these elements independently and do not offer any interplay between them. Our goal was to establish a promoter/transgene combination that would result in improvement in both expression and therapeutic effect by utilizing the transc...

journal_title：Cancer gene therapy

authors： Strauss BE,Bajgelman MC,Costanzi-Strauss E

更新日期：2005-12-01 00:00:00

abstract：:The Holliday Junction-Recognition Protein (HJURP) was reported as overexpressed in several cancers and also strongly correlated with poor prognosis of patients, especially in glioblastoma (GBM), the most common and deadly type of primary brain tumor. HJURP is responsible for loading the histone H3 variant-the Centrome...

journal_title：Cancer gene therapy

authors： Serafim RB,Cardoso C,Di Cristofaro LFM,Pienna Soares C,Araújo Silva W Jr,Espreafico EM,Paçó-Larson ML,Price BD,Valente V

更新日期：2020-05-01 00:00:00

abstract：:We have developed unique replication-competent retroviral (RCR) vectors based on murine leukemia virus that provide improved efficiency of viral delivery, allow for long-term transgene expression and demonstrate an intrinsic selectivity for transduction of rapidly dividing tumor cells. The purpose of this study was to...

journal_title：Cancer gene therapy

authors： Kikuchi E,Menendez S,Ozu C,Ohori M,Cordon-Cardo C,Logg CR,Kasahara N,Bochner BH

更新日期：2007-03-01 00:00:00

abstract：:Drug metabolizing transgene products, which activate bioreductive cytotoxins, can be used to target treatment-resistant hypoxic tumors. The prodrug AQ4N is bioreduced in hypoxic cells by cytochrome P450s (CYPs) to the cytotoxin AQ4. Previously we have shown that intra-tumoral injection of CYP3A4 and CYP2B6 transgenes ...

journal_title：Cancer gene therapy

authors： Yakkundi A,McErlane V,Murray M,McCarthy HO,Ward C,Hughes CM,Patterson LH,Hirst DG,McKeown SR,Robson T

更新日期：2006-06-01 00:00:00

abstract：:The DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) is epigenetically silenced in some tumors by MGMT gene promoter methylation. MGMT-hypermethylated solid tumors have enhanced susceptibility to the cytotoxic effects of alkylating chemotherapy such as temozolomide, compared with non-methylated tumors. ...

journal_title：Cancer gene therapy

authors： Ambady P,Wu YJ,Walker JM,Kersch C,Pagel MA,Woltjer RL,Fu R,Muldoon LL,Neuwelt EA

更新日期：2017-08-01 00:00:00

abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

journal_title：Cancer gene therapy

authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

更新日期：2020-05-01 00:00:00

abstract：:Chemotherapy is the preferred treatment for malignancies. However, a successful long-term use of chemotherapy is often prevented by the development of drug resistance. Many mechanisms such as gene mutation, DNA methylation and histone modification have important roles in the resistance of cancer cells to chemotherapeu...

journal_title：Cancer gene therapy

authors： Ma J,Dong C,Ji C

更新日期：2010-08-01 00:00:00

abstract：:Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen. We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modula...

journal_title：Cancer gene therapy

authors： Gan R,Yang Y,Yang X,Zhao L,Lu J,Meng QH

更新日期：2014-07-01 00:00:00

abstract：:We have constructed and tested five recombinant adenoviruses (Ads) that express a variety of immunomodulators, including CD40 ligand (CD40L), a potent costimulator of several components of the immune system. We demonstrate that CD40L expressed from Ad in K1735 mouse melanoma cells leads to a strong reduction in tumori...

journal_title：Cancer gene therapy

authors： Peter I,Nawrath M,Kamarashev J,Odermatt B,Mezzacasa A,Hemmi S

更新日期：2002-07-01 00:00:00

abstract：:CD70 (CD27 ligand (CD27L)), CD153 (CD30L), and CD154 (CD40L) are members of the tumor necrosis factor family of costimulatory molecules and expressed on the surface of T cells that are important for both T- and B-cell help. We examined the capacity for expression of these tumor necrosis factor family members on tumor ...

journal_title：Cancer gene therapy

authors： Couderc B,Zitvogel L,Douin-Echinard V,Djennane L,Tahara H,Favre G,Lotze MT,Robbins PD

更新日期：1998-05-01 00:00:00

abstract：:The Ki-ras gene is frequently mutated and/or overexpressed in human cancer. Since it is suspected to play a key role in the pathogenesis of many tumors, there is interest to search for strategies aiming at the specific inhibition of this oncogene. In this paper, we investigated the capacity of a 20 mer G-rich oligonuc...

journal_title：Cancer gene therapy

authors： Cogoi S,Ballico M,Bonora GM,Xodo LE

更新日期：2004-07-01 00:00:00

abstract：:We examined the host immune response to the poorly immunogenic B16-BL6 melanoma, which was transduced to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) (450 ng/10(6)/24 h). Tumor growth after subcutaneous inoculation was not significantly altered, although an influx of neutrophils and monocytes/macr...

journal_title：Cancer gene therapy

authors： Arca MJ,Krauss JC,Aruga A,Cameron MJ,Shu S,Chang AE

更新日期：1996-01-01 00:00:00

abstract：:Interleukin-10 (IL-10) is a T helper type 2 (Th2) cytokine that suppresses Th1-mediated, cell-mediated immune responses and reciprocally enhances antibody-mediated responses. Previous studies, however, demonstrated that forced expression of the IL-10 gene in tumor cells could unexpectedly produce antitumor effects. We...

journal_title：Cancer gene therapy

authors： Kawamura K,Bahar R,Natsume W,Sakiyama S,Tagawa M

更新日期：2002-01-01 00:00:00

abstract：:Bcl-2 is associated with resistance to radiotherapy in prostate cancer. It was recently demonstrated that transduction of LNCaP prostate cells with the PTEN gene resulted in Bcl-2 downregulation. We hypothesized that forced expression of PTEN in prostate cancer cells would sensitize cells to radiation, downregulate Bc...

journal_title：Cancer gene therapy

authors： Rosser CJ,Tanaka M,Pisters LL,Tanaka N,Levy LB,Hoover DC,Grossman HB,McDonnell TJ,Kuban DA,Meyn RE

更新日期：2004-04-01 00:00:00

abstract：:Prostate cancer is the second most common cancer in men globally. Prostate cancer patients at advanced stages are usually treated with androgen deprivation therapy (ADT). However, with disease progression, it often becomes the incurable castration-resistant prostate cancer (CRPC). JC polyomavirus (JCPyV) is a human DN...

journal_title：Cancer gene therapy

authors： Lin MC,Wang M,Chou MC,Chao CN,Fang CY,Chen PL,Chang D,Shen CH

更新日期：2019-07-01 00:00:00

abstract：:Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to a...

journal_title：Cancer gene therapy

authors： Sanlioglu AD,Koksal IT,Karacay B,Baykara M,Luleci G,Sanlioglu S

更新日期：2006-01-01 00:00:00

abstract：:Adenoviral technology has been thoroughly evaluated for delivering genetic material to tumor tissue and the surrounding microenvironment. Almost any gene can be cloned into an adenovirus (Ad) vector, which when combined with strong, constitutively active promoters permit up to a million-fold amplification of the trans...

journal_title：Cancer gene therapy

authors： Card PB,Hogg RT,Gil Del Alcazar CR,Gerard RD

更新日期：2012-07-01 00:00:00

abstract：:Cis-diamminedichloroplatinum(II) increased in vivo lipofection efficiency of tumor cells with a target gene, interferon gamma (IFN gamma), in a murine metastatic ovarian carcinoma model. The expression of IFN gamma gene in ascitic tumors reached a peak at day 11 after cisplatin treatment and lasted over 1 week. A loca...

journal_title：Cancer gene therapy

authors： Son K

更新日期：1997-11-01 00:00:00

abstract：:Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301...

journal_title：Cancer gene therapy

authors： Watanabe Y,Hashimoto Y,Kagawa S,Kawamura H,Nagai K,Tanaka N,Urata Y,Fujiwara T

更新日期：2012-11-01 00:00:00

abstract：:Most cancer vaccines to date have made use of common tumor antigens or allogenic cancer cell lines. The majority of tumor antigens may, however, be unique patient-specific antigens. Dendritic cells (DCs) are the most potent antigen-presenting cells known. The present report is a full-scale preclinical evaluation of au...

journal_title：Cancer gene therapy

authors： Kyte JA,Kvalheim G,Aamdal S,Saebøe-Larssen S,Gaudernack G

更新日期：2005-06-01 00:00:00

abstract：:Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ3...

journal_title：Cancer gene therapy

authors： Furukawa Y,Takasu A,Yura Y

更新日期：2017-09-01 00:00:00

abstract：:Interferon-gamma (IFN-γ) exhibits biological activities that are considered to have important roles in tumor suppression. Therefore, the IFN-γ gene is a potential candidate for in vivo cytokine gene therapy against skin cancer. The present study evaluated the efficacy of a hydrodynamics-based IFN-γ gene transfection f...

journal_title：Cancer gene therapy

authors： Ko JH,Jung BG,Park YS,Lee BJ

更新日期：2011-09-01 00:00:00

abstract：:Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a system...

journal_title：Cancer gene therapy

authors： Peng DJ,Sun J,Wang YZ,Tian J,Zhang YH,Noteborn MH,Qu S

更新日期：2007-01-01 00:00:00

abstract：:Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a gamma(1)34.5-deficient herpes simplex virus type 1 (HSV-1) R849 f...

journal_title：Cancer gene therapy

authors： Naito S,Obayashi S,Sumi T,Iwai S,Nakazawa M,Ikuta K,Yura Y

更新日期：2006-08-01 00:00:00

abstract：:Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such ...

journal_title：Cancer gene therapy

authors： Chen G,Zhou J,Gao Q,Huang X,Li K,Zhuang L,Huang M,Xu G,Wang S,Lu Y,Ma D

更新日期：2006-10-01 00:00:00

abstract：:A novel gene, HA117, was discovered in our previous work. Using the pSOS-HUS vector method which we designed at previous study, we screened for small interfering RNAs (siRNAs) that targeted HA117. The pSOS-HUS siRNA screening results were verified and a delivery system was developed that contained a recombinant adenov...

journal_title：Cancer gene therapy

authors： Zheng GH,Luo Q,Jin XQ,Guo YX,Xu YH

更新日期：2011-09-01 00:00:00

abstract：:Oncolytic virotherapy has shown substantial promises as an alternative therapeutic modality for solid tumors in both preclinical studies and clinical trials. The main therapeutic activity of virotherapy derives from the direct lytic effect associated with virus replication and the induction of host immune responses to...

journal_title：Cancer gene therapy

authors： Fu X,Tao L,Rivera A,Xu H,Zhang X

更新日期：2011-11-01 00:00:00

abstract：:The present study was designed to investigate the upstream transcription factors (TFs) and the signature genes in cholangiocarcinoma (CCA), providing better clues on the regulatory mechanisms and therapeutic applications. Gene expression data sets of CCA were searched in the Gene Expression Omnibus database for integr...

journal_title：Cancer gene therapy

authors： Yang L,Feng S,Yang Y

更新日期：2016-12-01 00:00:00

abstract：:Cytotoxicity is an important function of the immune system that results in the destruction of cellular targets by humoral and/or cellular mechanisms. We wanted to assess the possibility of targeting the lytic function of immune cells toward cancer cells, which express the gene coding for a known tumor antigen (Ag) (GA...

journal_title：Cancer gene therapy

authors： Paul S,Bizouarne N,Dott K,Ruet L,Dufour P,Acres RB,Kieny MP

更新日期：2000-04-01 00:00:00